GlaxoSmithKline plc’s (GSK) “Neutral” Rating Reiterated at Citigroup Inc.
GlaxoSmithKline plc (LON:GSK)‘s stock had its “neutral” rating restated by analysts at Citigroup Inc. in a report issued on Friday. They presently have a GBX 1,700 ($21.96) price target on the stock. Citigroup Inc.’s price objective would suggest a potential upside of 13.79% from the stock’s current price.
A number of other equities research analysts also recently weighed in on GSK. UBS AG set a GBX 1,600 ($20.66) price target on shares of GlaxoSmithKline plc and gave the stock a “neutral” rating in a research note on Monday, May 15th. Credit Suisse Group lowered their target price on shares of GlaxoSmithKline plc from GBX 1,775 ($22.92) to GBX 1,725 ($22.28) and set a “neutral” rating for the company in a research note on Wednesday. Goldman Sachs Group, Inc. (The) set a GBX 1,900 ($24.54) target price on shares of GlaxoSmithKline plc and gave the company a “buy” rating in a research note on Tuesday, August 8th. Deutsche Bank AG set a GBX 1,610 ($20.79) target price on shares of GlaxoSmithKline plc and gave the company a “neutral” rating in a research note on Tuesday, August 8th. Finally, Jefferies Group LLC reaffirmed a “buy” rating on shares of GlaxoSmithKline plc in a research note on Wednesday. Four analysts have rated the stock with a sell rating, ten have issued a hold rating and eight have given a buy rating to the stock. GlaxoSmithKline plc has a consensus rating of “Hold” and a consensus target price of GBX 1,714.48 ($22.14).
GlaxoSmithKline plc (GSK) traded down 1.09% during trading on Friday, reaching GBX 1494.00. 5,910,086 shares of the company were exchanged. GlaxoSmithKline plc has a 52-week low of GBX 1,446.50 and a 52-week high of GBX 1,745.56. The firm’s market cap is GBX 73.03 billion. The firm has a 50-day moving average of GBX 1,521.96 and a 200-day moving average of GBX 1,615.99.
GlaxoSmithKline plc (LON:GSK) last posted its quarterly earnings results on Wednesday, July 26th. The company reported $0.52 earnings per share for the quarter, missing the Zacks’ consensus estimate of $26.23 by $25.71. GlaxoSmithKline plc had a return on equity of 295.67% and a net margin of 16.56%. On average, equities analysts forecast that GlaxoSmithKline plc will post $110.99 EPS for the current year.
COPYRIGHT VIOLATION NOTICE: “GlaxoSmithKline plc’s (GSK) “Neutral” Rating Reiterated at Citigroup Inc.” was first reported by American Banking News and is owned by of American Banking News. If you are accessing this story on another domain, it was illegally stolen and reposted in violation of US and international trademark and copyright laws. The legal version of this story can be read at https://www.americanbankingnews.com/2017/09/09/glaxosmithkline-plcs-gsk-neutral-rating-reiterated-at-citigroup-inc.html.
In other GlaxoSmithKline plc news, insider Patrick Vallance bought 861 shares of GlaxoSmithKline plc stock in a transaction that occurred on Friday, July 14th. The stock was acquired at an average price of GBX 1,618 ($20.90) per share, for a total transaction of £13,930.98 ($17,991.71). Also, insider Manvinder Singh Banga bought 2,267 shares of GlaxoSmithKline plc stock in a transaction that occurred on Wednesday, July 26th. The shares were acquired at an average price of GBX 1,599 ($20.65) per share, with a total value of £36,249.33 ($46,815.61). Insiders have purchased 3,144 shares of company stock valued at $5,043,015 in the last 90 days.
GlaxoSmithKline plc Company Profile
GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.
Receive News & Ratings for GlaxoSmithKline plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline plc and related companies with MarketBeat.com's FREE daily email newsletter.